Introduction
Malignant gliomas are the most common neoplasms in the central nervous system. The average life expectancy after diagnosis is usually less than 1 year, which demonstrates the aggressiveness of the tumor (Schoenberg, 1983) . DNA-damaging drugs such as cisplatin, however, have been shown to induce apoptosis to some extent in tumors including malignant glioblastoma cells (Kaufman, 1989; Eastman, 1990; Fritsche et al., 1993; Kondo et al., 1995a,b,c,d) . Increasing the susceptibility of tumor cells to apoptotic cell death, therefore, is of importance to the outcome of therapy (Lotem and Sachs, 1993) . Despite recent attempts to improve chemotherapeutic approaches, success in the treatment of brain tumors remains limited. A common approach, therefore, is to combine two or more drugs in an attempt to increase the ecacy of the treatment.
Recently, we and others demonstrated that some of calcium channel blockers signi®cantly enhance the antitumor eect of cisplatin on tumor cells (Ikeda et al., 1987; Onoda et al., 1989; Kondo et al., 1995a and c) . The main problem with this form of chemosensitisation is the inability to attain an eective plasma level in the patient without causing cardiovascular toxicity (Ozols et al., 1987) . Therefore, it is absolutely necessary to explore other novel approaches that render tumors more susceptible to the drugs used in cancer treatment.
Telomeres are located at the ends of chromosomes, and are composed of tandem DNA repeats of the sequence (TTAGGG) n . Normal human somatic cells lose some of telomeric repeats with each cell doubling. When telomeres reach a critical lower length, the cells generally enter senescence. In some studies, it is shown that reduction in telomere length results in genomic instability (Blackburn, 1991; Harley et al., 1991) . To overcome this limitation of cell division, most malignant tumor cells express telomerase which compensates for the progressive loss in telomeres (Kim et al., 1994; Broccoli et al., 1995; Counter et al., 1995; Hiyama et al., 1995a,b) . Telomerase, a ribonucleic acid-protein complex, adds telomeric repeats to the ends of chromosomes (Greider and Blackburn, 1985) . Overall, 70 ± 95% of malignant tumor cells express relatively high level of telomerase (Kim et al., 1994; Broccoli et al., 1995; Counter et al., 1995; Hiyama et al., 1995a Hiyama et al., ,b, 1997 Langford et al., 1995; De Masters et al., 1997) . As telomeres play a role in protecting DNA, there is the possibility that, if telomerase activity is inhibited in tumor cells, they might be more vulnerable to DNA-damaging agents. To investigate this hypothesis, we examined the association between telomerase activity and sensitivity to cisplatin. First, we show that human malignant glioblastoma U87-MG cells are more sensitive to cisplatin than U251-MG cells (P50.01). Interestingly, U87-MG cells did not express telomerase activity, whereas telemerase was highly detected in U251-MG cells. To test our hypothesis, we constructed an antisense vector (pBabe anti-telo) for the human telomerase RNA and transfected it into U251-MG cells. Then, we established four stable clones without telomerase activity. Surprisingly, these clones exhibited increased susceptibility to cisplatin-induced apoptotic cell death. We suggest that inhibition of telomerase may represent a new chemosensitisation for tumors resistant to anticancer drugs.
Results and discussion

Induction of apoptosis in malignant glioma cells by cisplatin
Exponentially growing U87-MG and U251-MG cells were treated with cisplatin. Using a modi®ed MTT assay, as shown in Figure 1a , cisplatin inhibited the viability of tumor cells in a dose-dependent manner. The IC 50 of cisplatin for U87-MG and U251-MG cells was 1.5 mg/ml and 8.0 mg/ml, respectively. Thus, U251-MG cells are ®ve times more resistant to cisplatin than U87-MG cells. Three days after the addition of cisplatin (10.0 mg/ml), 66% of U87-MG cells and 48% of U251-MG cells displayed typical apoptotic morphology (membrane blebbing, nuclear condensation and fragmentation) (Figure 1b) . These results indicated that U251-MG cells were more resistant to cisplatin-induced apoptosis than U87-MG cells (P50.01).
Eect of telomerase inhibition on cisplatin-induced apoptosis
The TRAP assay (cell extracts of 20 ng protein for each) was used to determine the telomerase activity in the two glioma cell lines. As shown in Figure 2 , U87-MG cells did not express telomerase activity, compared with U251-MG cells expressing telomerase. Internal standard bands were detected in all samples, which excludes a possibility of false-negative results due to Taq polymerase inhibitor. The intensity of the bands of positive control was assigned a value of 100. The relative intensity of U251-MG or U87-MG cells was 90 and 4, respectively. At a higher concentration of cell extracts (1.0 mg protein), telomerase was detected in U87-MG cells (data not shown). Since U251-MG cells were more resistant to cisplatin-induced apoptosis, we hypothesized that telomerase may have an important role in the regulation of cisplatin-induced apoptosis in glioma cells. To test this hypothesis, we used the telomerase antisense expression vector, and determined the eect of inhibiting telomerase on cisplatin-induced apoptosis. U251-MG cells had primarily been transfected with the pBabe anti-telo plasmid and four clones (A to D) were isolated. As shown in Figure 3 , all of these clones (at 40 doublings after transfection) did not express telomerase activity (intensities of 5 to 10 compared to positive control) when compared with parental U251-MG cells and U251-MG transfected with the control pBabe-puro plasmid. A similar result was obtained at 15 and 60 doublings after transfection (data not shown). To determine whether inhibition of telomerase aected cisplatin-induced cell death, cells from clones (A to D) were treated with various concentrations of cisplatin. As shown in Figure 4 clones was 2.5 to 3.5 mg/ml, whereas that of parental U251-MG cells and U251-MG transfected with the control vector was 8.0 or 8.2 mg/ml, respectively. It means that IC 50 in the clones was reduced to 31 ± 44% of parental U251-MG cells. Additionally, in those cells showing inhibition of telomerase activity, the induction of apoptotic cell death was increased when compared to parental U251-MG cells or U251-MG transfected with the control vector (P50.01) (Figure 4b ). These results indicate that blocking telomerase increases the susceptibility of malignant glioma cells to cisplatininduced apoptosis.
Telomerase activity has been detected frequently in the majority of tumors (Kim et al., 1994; Broccoli et al., 1995; Counter et al., 1995; Hiyama et al., 1995a,b) . Avoidance of telomerase shortening by expression of telomerase may contribute to the immortal phenotype. On the other hand, some immortal cell lines without detectable telomerase activity have been described that they are characterized by long telomeres (Rogan et al., 1995; Strahl and Blackburn, 1996) . These observations indicate the presence of a telomerase-independent mechanism for telomere length maintenance in these tumors. However, about 70 ± 95% of the tumors including malignant gliomas express high levels of telomerase (Kim et al., 1994; Broccoli et al., 1995; Counter et al., 1995; Hiyama et al., 1995a Hiyama et al., ,b, 1997 Langford et al., 1995; De Masters et al., 1997) . More recently, HeLa cells transfected with an antisense human telomerase were found to lose telomeric DNA and to die after 23 to 26 doublings (Feng et al., 1995) . Certainly, some subpopulations of clones (A to D) that we used in this study underwent apoptosis after 30 to 35 doublings following transfection (unpublished data). We demonstrate here that subpopulations of cells which have escaped from apoptotic crisis as a result of telomerase inactivation, show the increased susceptibility to cisplatin, although the precise molecular mechanism behind this remains unclear.
Telomerase protects cellular DNA from the speci®c kind of genomic instability that results from erosion of the chromosome ends, and it prevents the death crisis that occurs in senescent cells as the ®nal response to P]dCTP and, after addition of the CX primer, elongated TS oligonucleotides were ampli®ed by PCR in the presence of an internal TRAP assay standard (ITAS). Reaction products were resolved on a 10% polyacrylamide gel.
Extracts of four clones (A to D) were isolated at 40 doublings after transfection
Inhibition of telomerase accelerates apoptosis by cisplatin Y Kondo et al such instability (Blackburn, 1991; Harley et al., 1991; Broccoli et al., 1995; Counter et al., 1995) . It may be dicult to generalize from this function of telomerase to the idea that telomerase protects from all DNA damages. However, it is presumed that inhibition of telomerase will increase the global genomic instability or shift the regulation of proliferation toward dierentiation, senescence, or apoptosis. Cisplatin is shown to induce apoptosis in some types of cells including malignant gliomas (Kaufman, 1989; Eastman, 1990; Fritsche et al., 1993; Kondo et al., 1995a,b,c,d) . Therefore, it may be reasonable that inhibition of telomerase increases the susceptibility of tumors to DNA damaging drugs which induce apoptosis. More recently, Kato et al. (1997) report that combined use of telomerase antisense and DNA damaging drugs inhibited growth of lung cancer cells. Our ®ndings support their demonstration. The fact that the majority of glioblastoma multiforme (Langford et al., 1995; De Masters et al., 1997) and their derived cell lines (Kim et al., 1994) have telomerase activity, whereas telomerase was undetectable in non-neoplastic brain tissues (Sallinen et al., 1997) and cultured astrocytes and low grade astrocytes (unpublished data), suggesting that telomerase in malignant gliomas may be secondarily reactivated, but not a relic from the embryonic lineage. Therefore, inhibition of telomerase may direct malignant gliomas to dierentiation, if apoptosis is not induced.
Recently, several biochemical alterations have been demonstrated relating to cisplatin sensitivity: (a) cellular accumulation of cisplatin; (b) expression of cell-surface glycoprotein analogous to P-glycoprotein; (c) levels of glutathione (GSH) or of glutathione-Stransferase activity; (d) levels of intracellular metallothioneins (MTs); and (e) ability to repair DNA (Kelly and Rozencweig, 1989; Andrew and Howell, 1990; Kawai et al., 1990; Perez et al., 1990; TimmerBosscha et al., 1992; Gately and Howell, 1993) . Further studies are necessary to determine whether and how inhibition of telomerase aects these aspects. Additionally, from the viewpoint of apoptosis pathway, we previously reported that bcl-2 gene or MDM2 gene confers the resistance of malignant glioblastoma cells to cisplatin-induced apoptosis (Kondo et al., 1995b) . Mandal and Kumar (1997) have recently reported upregulation of telomerase activity by stable overexpression of Bcl-2. We are currently determining the association among these genes, telomerase activity, and apoptosis. Recent reports demonstrate that p53 is required for the ecient activation of apoptosis following chemotherapy (Lowe et al., 1993a,b) . It is therefore possible that the p53 status of U87-MG (wild-type) and U251-MG cells (mutant) is involved in not only sensitivity to apoptosis, but also telomerase activity. Taking together, telomerase could be an important new target for anti-cancer therapy, at least for chemosensitisation. 
Materials and methods
Tumor cells
Human glioblastoma U87-MG (wild-type p53, Kondo et al., 1996) and U251-MG cells (mutant p53, Van Meir et al., 1994) were used in this study. Tumor cells were cultured in Dulbecco's modi®ed Eagle's medium (GIBCO BRL, Grand Island, NY) supplemented with 10% heat-inactivated fetal calf serum (GIBCO BRL), 4 mM glutamine, 50 U/ml penicillin and 50 mg/ml streptomycin.
Reagent
Cisplatin was the generous gift of Nippon Kayaku Co. (Tokyo, Japan). It was obtained in powder form, from which 0.4 mg/ml stock solution was prepared in normal saline as described previously (Kondo et al., 1995b) .
Cell viability
The cytotoxic eect of cisplatin on tumor cells was quanti®ed using a modi®ed MTT (Boehringer Mannheim Biochemicals, Indianapolis, IN) colorimetric assay (Kondo et al., 1995b) . Tumor cells were seeded at 10 4 cells/well (0.1 ml) in 96-well,¯at-bottom plates (Corning Glass Co., Corning, NY) and incubated overnight at 378C. Then, cisplatin was added (10 ml per well) to wells to achieve desired concentrations. After incubation for 3 days, MTT assay was performed. The statistical signi®cance of ®ndings was assessed using the unpaired Student's t-test.
Apoptotic features
To determine whether tumor cells treated with cisplatin displayed an apoptotic morphology, tumor cells were stained with Hoechst 33258 (8 mg/ml) as described previously (Kondo et al., 1995d) . Five hundred cells were counted and scored for the incidence of apoptotic chromatin changes (blebbing, fragmentation and condensation) under U.V.-¯uorescence microscopy. The statistical signi®cance of ®ndings was assessed using the unpaired Student's t-test.
Telomerase activity (TRAP) assay
The telomerase assay was performed by a method described previously (Kim et al., 1994) with some minor modi®cations. Tumor cells were seeded at 10 4 cells/well (0.1 ml) in 96-well microplate (Corning, NY) and incubated over night at 378C. Cells were washed once in PBS, and homogenized in 50 ml of ice-cold lysis buer [10 mM Tris-HCl (pH 7.5), 1 mM MgCl 2 , 1 mM EGTA, 0.1 mM PMSF, 5 mM b-mercaptoethanol, 0.5% CHAPS, 10% glycerol]. After 30 min of incubation on ice, the lysates were centrifuged at 11 000 g for 15 min at 48C, and the supernatant was rapidly frozen and stored 7808C. The concentration of protein was measured with the use of the BioRad Protein Assay (Richmond, CA), and an aliquot of extract containing 5 mg/ml of protein was used for each telomerase assay. For RNase treatment, 5 ml of extract was incubated with 1 ml RNase A (1 mg/ml) for 30 min at 258C. Two ml of each extract was assayed in 50 ml of reaction mixture containing 20 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 , 63 mM KCl, 0.05% Tween-20, 1 mM EGTA, 50 mM deoxynucleoside triphosphates, 0.2 to 0.4 ml of [a-32 P]dCTP (10 mCi/ml, 3000 Ci/mM), 0.1 mg of TS oligonucleotides (5'-AATCCGTCGAGCAGAGTT-3'), 1 mg of T4 gene 32 protein (Boehringer Mannheim) and 2 units of Taq DNA polymerase (Boehringer Mannheim). After a 30 min incubation at room temperature for telomerase-mediated extension of the TS primer, 0.1 mg of CX oligonucleotides (5'-CCCTTACCCTTACCCT-TACCCTAA-3') was added. The reaction mixture was then subjected to PCR ampli®cation in a thermal cycler with 30 cycles at 948C for 30 s, 508C for 30 s, and 728C for 1.5 min in the presence of an internal TRAP assay standard (ITAS, 36 bp; Oncor, Gaithersburg, MD). Positive control (Oncor) was used in all assays. The PCR product was electrophoresed in 0.56tris-borate EDTA on a 10% polyacrylamide gel. The gels were then dried, and autoradiography was performed for 24 h at 7708C. Radioactivity was also quantitated with a Molecular Dynamics PhosphorImager (Sunnyvale, CA).
Antisense human telomerase expression vector
The plasmid (p10-3-hTR) containing cDNA of the antisense of human telomerase (Feng et al., 1995) was digested with EcoRI and a 200 bp EcoRI DNA fragment (1 to 185 nucleotides of antisense telomerase) was puri®ed. The fragment was inserted into the EcoRI site of the plasmid pBabe-puro (pBabe anti-telo). U251-MG cells were plated at a density of 5610 5 cells/ml 1 day prior to transfection of pBabe anti-telo vector. Cells were transfected with the pBabe anti-telo plasmid by using Lipofectamine-mediated gene transfer as previously described (Kondo et al., 1995b) . Forty-eight hours after transfection, selection with puromycin was started. To determine whether stable clones with the pBabe-anti-telo have decreased telomerase activity, telomerase assay was performed as described above. Six puromycin-resistant clones (four with undetectable telomerase activity, and two with a high telomerase as parental U251-MG cells) were obtained. After 30 doublings following transfection, some subpopulations of four clones without telomerase (A to D) underwent apoptosis over a period of 1 week. In this study, four clones at 40 to 45 doublings after transfection were tested.
Abbreviations cisplatin, cis-diamminedichloroplatinum; MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium bromide; Hoescht 33258, the DNA-binding¯uorochrome bis (benzimide) trihydro-chloride; and IC 50 , concentration at which 50% inhibition of cell viability can be induced when treated for 72 h as compared with control.
